Signal-Based Selling · healthcareJul 20269 min read342 words

Signal-based selling vs the traditional approach: what actually beats what for healthcare and life sciences

A head-to-head on signal-based selling versus the incumbent approach — where each wins, where each loses, and how to combine them. Written for commercial leaders at healthtech, medtech, and life-sciences companies.

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install signal-based selling has to reflect that reality from day one.

The debate about signal-based selling is often framed as replacement — new model wipes out old. That framing is wrong. The right question is where each approach wins.

Signal-based selling wins on speed of learning, targeting precision, and cost per outcome. It is routing sales action to accounts showing observable in-market behavior, and it compounds in ways the traditional approach cannot match.

The traditional approach wins on relationship depth, brand consistency, and situations where the buyer has already self-identified. Ignoring that is why some teams' first signal-based selling attempt underperforms — they replace the wrong parts.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Signal-based selling is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Combine them deliberately. Use signal-based selling to find and qualify; use the traditional approach to close and expand. The seam between them is where most pipeline is lost or won.

Metric to watch when running both: hours from signal to first human touch, plus source attribution. The two approaches should not cannibalise each other; if they do, your handoff is broken.

The failure mode of running both is surfacing so many signals reps ignore all of them — usually because the traditional team feels threatened and the new model is starved of context.

Companies that get this right end up with a hybrid engine that outperforms either pure model. Companies that pick one and evangelise it lose to the ones that combine.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing signal-based selling properly rather than half-heartedly across three vendors.

signal based sellingbuying signalsintent datasignal based selling vs traditionalsignal based selling comparisonsignal based selling for healthcare and life scienceshealthcare signal based sellinghealthcare and life sciences growth

Frequently asked questions

Signal-Based Selling · healthcare — answered

Does signal-based selling work for healthcare and life sciences?
Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
Is signal-based selling a replacement for the traditional approach?
No — the two combine. Use the new model to find and qualify, the traditional model to close and expand.
Where does the traditional approach still win?
Relationship depth, brand-critical moments, and already-warm buyers.
How do I run both without conflict?
Clear handoff at a defined stage, shared metrics, and no source-based commissions that create tribal loyalty.
What is the failure mode of combining them?
Surfacing so many signals reps ignore all of them — usually a broken handoff or a threatened incumbent team.
What is the healthcare specific pitfall with signal-based selling?
Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.

Growth Broker editorial

Filed under signal-based selling · healthcare

Up next

Signal-based selling for startups under 20 people for healthcare and life sciences

Read piece

Ready to broker your growth?

Book a Growth Call